Charting a new course in inflammatory and autoimmune disease medicine.
Navigator Medicines is a clinical-stage biotech advancing bispecific antibodies to bring new hope to people living with complex inflammatory disorders and autoimmune diseases.
We develop bispecific antibodies that target two key drivers of inflammation to deliver better, longer-lasting results for patients.
News
September 29, 2026
Navigator Medicines Presents New Data at EADV 2026 as Bispecific Antibody Program Advances at Speed in Hidradenitis Suppurativa
>> READ MORE
March 27, 2026
Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026
>> READ MORE
January 8, 2026
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials
>> READ MORE